ZoetisMEX:ZTS +1.14%69 Shareholder Yield % is 9.55% as of Mar. 2026, which is 753% above its 10-year median of 1.12. GuruFocus rates MEX:ZTS with a GF Score™ of 69/100 and a GF Value™ of MXN3,415.79 (Significantly Undervalued). Among 969 Drug Manufacturers companies, Zoetis ranks better than 91.33% on this metric.
Shareholder Yield % is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. It is a measure of shareholder return.
As of today, Zoetis's Shareholder Yield % was 9.55%.
Zoetis (MEX:ZTS) Shareholder Yield % Explanation
Shareholder Yield % is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. The term was coined by William W. Priest of Epoch Investment Partners in a paper in 2005 entitled The Case for Shareholder Yield as a Dominant Driver of Future Equity Returns. William Priest indicated that "shareholder yield is a term that we came up with to reflect the various ways dividends can be paid to owners of a business in a publicly-traded company."
Dividend Yield % shows how much a company pays out in dividends each year relative to its stock price, which is most obvious form of shareholder return.
Buyback Yield % is the net repurchase of shares outstanding over the market capital of the company. Shares repurchases also increase shareholder value by returning the money back to shareholders.
Net Debt Paydown Yield % is the change in average of four quarters of company's total debt over a company's market cap. Assuming the total value of a company remains that same, shareholder value is increased as debt is reduced.
Zoetis Shareholder Yield % Related Terms
Zoetis Shareholder Yield % Historical Data
* Premium members only.
The historical data trend for Zoetis's Shareholder Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:ZTS vs UTHR, VTRS, NBIX: Shareholder Yield % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Zoetis's Shareholder Yield %, along with its competitors' market caps and Shareholder Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zoetis Shareholder Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Zoetis's Shareholder Yield % distribution charts can be found below:
* The bar in red indicates where Zoetis's Shareholder Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* All the data are calculated by TTM values. Note that if a companies is traded in several exchanges, then we calculate the company level data for Shareholder Yield % using the primary share class stock data. The calculation result in definition page is for demonstration purpose only, and it's showing the share class level data. Therefore, the numbers in the calculation may differ from elsewhere if the stock is not a primary share.
Zoetis (MEX:ZTS) has a Shareholder Yield % of 9.55% as of Mar. 2026. Shareholder Yield is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. View historical data on Zoetis and its competitors. This is 753% above median its historical median of 1.12. According to the industry distribution chart, Zoetis ranks #84 out of 969 companies in the Drug Manufacturers industry, placing it in the top 8.7%.
Is Zoetis' Shareholder Yield % too high?
Zoetis' current Shareholder Yield % of 9.55% is 753% above median its 10-year median of 1.12. The Drug Manufacturers industry median Shareholder Yield % is 0.34. Zoetis' value of 9.55% is 2708.8% above this industry median. Based on the distribution chart, Zoetis ranks #84 out of 969 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Zoetis has a GF Score™ of 69/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Zoetis' Shareholder Yield % compare to UTHR and VTRS?
According to the Drug Manufacturers industry distribution chart, Zoetis ranks #84 out of 969 companies for Shareholder Yield %. This places Zoetis in the top 9% of its industry — outperforming the majority of peers. The industry median Shareholder Yield % is 0.34. Zoetis' value of 9.55% is 2708.8% above this benchmark. While the company's 10-year median is 1.12 vs. the industry median of 0.34, Zoetis has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shareholder Yield % for a Drug Manufacturers company?
The median Shareholder Yield % among Drug Manufacturers companies is 0.34, based on 969 companies in the industry. Companies in the top quartile (top 25%) have a Shareholder Yield % significantly above this median, while those in the bottom quartile fall well below. However, Shareholder Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zoetis's current Shareholder Yield % of 9.55% is 2708.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shareholder Yield % mean?
A high Shareholder Yield % can signal that a stock is expensive relative to its fundamentals. Shareholder Yield is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. View historical data on Zoetis and its competitors. For the Drug Manufacturers industry, the median Shareholder Yield % is 0.34 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zoetis's current Shareholder Yield % is 9.55%, which is 753% above median its own 10-year median of 1.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zoetis stock overvalued right now?
Based on GuruFocus' analysis, Zoetis (MEX:ZTS) is currently considered Significantly Undervalued. The stock's GF Value™ is MXN3,415.79, compared to a current price of MXN1,279.00 — trading 62.6% below its estimated fair value. The current Shareholder Yield % is 9.55%, which is 753% above median its 10-year median of 1.12 and 2708.8% above the Drug Manufacturers industry median of 0.34. Zoetis' overall GF Score™ is 69/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shareholder Yield % calculated?
Shareholder Yield % is calculated from a company's financial statements. For Zoetis (MEX:ZTS), the current Shareholder Yield % is 9.55% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zoetis (MEX:ZTS) Overvalued in 2026?
Based on GuruFocus' analysis, Zoetis stock appears to be undervalued.
The current stock price of MXN1,279.00 is trading 62.6% below its estimated GF Value™ of MXN3,415.79.
GuruFocus considers Zoetis to be Significantly Undervalued.
Key valuation signals for MEX:ZTS:
Shareholder Yield %: 9.55% (753% above median its 10-year median of 1.12)
GF Value™: MXN3,415.79 vs. price of MXN1,279.00 (62.6% below fair value)
Industry Position: 2708.8% above the Drug Manufacturers median (#84 of 969)
No single metric tells the full story. See the MEX:ZTS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on) and nearly 65% from companion animal (dogs, horses, cats) products. Its US business is skewed even more heavily toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
69GF Score
Get the complete analysis for MEX:ZTS
Shareholder Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:ZTS has been successfully added to your 
